Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
Rhea-AI Summary
Xenetic Biosciences (NASDAQ: XBIO) reported second quarter 2026 results and reiterated progress on its proprietary DNase platform in immuno-oncology. Royalty revenue for the three months ended June 30, 2026 rose about 12% to approximately $0.7 million, driven primarily by higher royalties under its sublicense agreement with Takeda. Research and development expenses declined roughly 16% to about $0.6 million, while general and administrative expenses increased around 64% to approximately $1.1 million, mainly due to legal costs related to an ongoing strategic review. Net loss for the quarter was about $0.9 million versus approximately $0.7 million a year earlier, and cash and cash equivalents totaled roughly $6.5 million at June 30, 2026, compared to about $7.9 million at December 31, 2025.
Operationally, Xenetic highlighted positive preclinical and translational data presented at ASCO 2026 showing DNase I enhanced CAR T-cell expansion, persistence, tumor control and survival in hematologic cancer models, expansion of collaborative research on DNase-mediated NET targeting, and approximately $1.5 million in royalty revenue generated in the first half of 2026.
Positive
- Royalty revenue $0.7M in Q2 2026, up ~12% YoY
- R&D expenses $0.6M in Q2 2026, down ~16% YoY
- $1.5M royalty revenue generated in the first six months of 2026
- Positive DNase I preclinical data showing enhanced CAR T-cell efficacy in hematologic models
- Israeli approvals obtained for exploratory DNase I plus CAR T-cell study in large B-cell lymphoma
Negative
- G&A expenses $1.1M in Q2 2026, up ~64% YoY on legal costs
- Net loss $0.9M in Q2 2026 vs. $0.7M in Q2 2025
- Cash $6.5M at June 30, 2026, down from $7.9M at December 31, 2025
News Explained
The release reports that collaboration partner PeriNess received Israeli Ministry of Health and institutional-review-board approval to conduct an investigator-initiated exploratory study of systemic recombinant human DNase I with anti-CD19 CAR-T therapy in large B-cell lymphoma, moving the program to an approved-to-conduct stage without stating that the study has begun.
Market reaction after 2Q26 earnings report: XBIO +4.74%
Following this news, XBIO has gained 4.74%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 23 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $2.98. Trading volume is exceptionally heavy at 25.0x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | 1Q26 earnings | Positive | +5.1% | Royalty growth, reduced expenses, narrower net loss, and increased cash balance |
| Mar 13 | FY25 earnings | Positive | +9.5% | Higher royalties, lower expenses, and year-end cash increase supported annual results |
| Nov 13 | 3Q25 earnings | Negative | -2.6% | Higher research spending and net loss accompanied quarterly royalty revenue growth |
| Aug 13 | 2Q25 earnings | Positive | +7.2% | Partnership expansion, clinical-study initiation, and lower quarterly operating expenses |
| May 14 | 1Q25 earnings | Positive | +2.0% | Revenue growth, lower operating expenses, and continued DNase clinical development |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The five tag-matched earnings events all showed positive price reactions, averaging 4.22%.
Key Terms
dnase i medical
car t-cell therapy medical
neutrophil extracellular traps medical
non-dilutive funding financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Expanded collaborative research initiatives reinforce the Company's long-term DNase development strategy
Ongoing generation of translational data designed to support future clinical development and deepen understanding of DNase I-mediated NET targeting
Continued royalty generation provides recurring, non-dilutive funding to support continued investment in core development programs
FRAMINGHAM, MA / ACCESS Newswire / August 7, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update on continued execution of its long-term strategy to advance its proprietary DNase platform through scientific collaboration and translational research.
Recent Highlights
Positive preclinical and translational data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating that DNase I significantly enhanced CAR T-cell expansion, persistence, tumor control and survival across preclinical hematologic cancer models
Announced that collaboration partner, PeriNess Ltd., received approval from the Israeli Ministry of Health and the respective Institutional Review Board to conduct an investigator-initiated exploratory study evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T-cell therapy in patients with large B-cell lymphoma at Tel Aviv Sourasky Medical Center
Received approximately
$1.5 million in royalty revenue during the first six months of 2026
"We continue to generate strong translational data as evidenced by what was presented at ASCO, further supporting the potential of DNase I as a differentiated adjunct therapy designed to improve the efficacy and durability of CAR T-cell therapies," said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic. "Throughout the second quarter, we continued expanding the scientific foundation supporting our proprietary DNase technology while prudently allocating capital toward activities designed to both inform future clinical development and advance our ongoing strategic review process. We believe this disciplined approach, combined with continued royalty revenue from our legacy PolyXen technology, positions Xenetic to pursue long-term opportunities that have the potential to create meaningful value for both patients and shareholders."
Xenetic is advancing its proprietary DNase platform as a differentiated approach designed to enhance the effectiveness of existing cancer therapies by targeting neutrophil extracellular traps (NETs), an increasingly recognized driver of tumor progression, immune suppression and therapeutic resistance. Through collaborations with leading academic institutions, the Company continues to expand the scientific understanding of NET biology while generating translational evidence intended to inform future clinical development and strengthen the long-term potential of its platform.
Summary of Financial Results for Second Quarter 2026
Royalty revenue for the three months ended June 30, 2026 increased approximately
Research and development expenses for the three months ended June 30, 2026 decreased approximately
General and administrative expenses for the three months ended June 30, 2026 increased approximately
Net loss for the quarter ended June 30, 2026 was approximately
The Company ended the second quarter of 2026 with approximately
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", "continues", "warrants", and other words of similar meaning, including, but not limited to, all statements regarding royalty revenue generation, our belief regarding positioning Xenetic to pursue long-term opportunities that have the potential to create meaningful value for both patients and shareholders, our focus on advancing DNase into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, expanding the scientific understanding of NET biology, our generation of translational data and the potential of DNase I as a differentiated adjunctive therapy designed to improve the efficacy and durability of CAR T-cell therapies. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; (6) risks and uncertainties as to the outcome and timing of the strategic review process being conducted by the Board and a special independent committee thereof, including the possibility that the Board may decide not to undertake a strategic alternative following the evaluation process, the Company's inability to consummate any proposed strategic alternative resulting from the review due to, among other things, market, regulatory and other factors, the potential for disruption to our business resulting from the review process, and potential adverse effects on the Company's stock price from the announcement, suspension or consummation of the evaluation process and the results thereof, as well as risks and uncertainties related to the potential impacts of consummation of a strategic transaction on the Company's current business operations, anticipated business strategy and product development plans; and (7) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View the original press release on ACCESS Newswire